P4HA2 and clear cell renal carcinoma: In terms of mutation frequency, P4HA2 showed mutation rates above 5% in Cholangiocarcinoma, Renal Clear Cell Carcinoma, and Endometrial Cancer, with Renal Clear Cell Carcinoma predominantly showing Amplification, Endometrial Cancer showing Mutation, while Breast cancer had mutation frequency below 1% (Figure 13D).